Back to search
Acquired Thrombotic Thrombocytopenic Purpura
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Acquired Thrombotic Thrombocytopenic Purpura trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Acquired Thrombotic Thrombocytopenic Purpura trials you may qualify forData about efficacy and safety of daratumumab in iTTP refractory or intolerant to standard immunosuppressive treatments are scarce. Therefore, the investigators…
This study aims to investigate whether genetic variation in the TNFAIP3 locus is associated with immune-mediated thrombotic thrombocytopenic purpura (iTTP), and…
The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune…
This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study w…
The objective of this national, prospective, multi-centre observational study is to describe the prescription rational and practice in Germany, confirm the effi…
The aim of the study is to evaluate the efficacy of a personalized caplacizumab regimen based on ADAMTS13 activity monitoring in adult acquired thrombotic throm…
The lack of ADAMTS13 is the only biological marker that is specific for aTTP diagnosis8 and the assessment of ADAMTS13 is of clinical importance because it is e…